Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
Amber KunkelFrank G CobelensTed CohenPublished in: PLoS medicine (2016)
If mortality benefits can be empirically verified, our results provide support for expanding bedaquiline access to all patients with MDR TB. Such expansion could improve patients' health, protect background MDR TB drugs, and decrease transmission, but would likely result in greater resistance to bedaquiline.
Keyphrases
- multidrug resistant
- drug resistant
- mycobacterium tuberculosis
- end stage renal disease
- public health
- ejection fraction
- chronic kidney disease
- newly diagnosed
- healthcare
- peritoneal dialysis
- prognostic factors
- mental health
- emergency department
- risk factors
- type diabetes
- drug induced
- cardiovascular events
- coronary artery disease
- adverse drug
- climate change
- health promotion
- data analysis